WAVE LIFE SCIENCES LTD. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $330.00K, a 44.44% decline year-over-year.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.93M, a 21.09% decline year-over-year.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $2.04M, a 195.80% increase year-over-year.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $594.00K, a 460.38% increase year-over-year.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, stock options exercised for fiscal 2025 was $14.87M, a 399.09% increase from fiscal 2024.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, stock options exercised for fiscal 2024 was $2.98M, a 485.27% increase from fiscal 2023.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, stock options exercised for fiscal 2023 was $509.00K, a 128.25% increase from fiscal 2022.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, stock options exercised for fiscal 2022 was $223.00K, a 10.80% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $330.00K 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $1.93M 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $14.87M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $2.04M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $594.00K 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $2.45M 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $2.98M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $690.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $106.00K 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $123.00K 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $509.00K 10-K · filed 2026-02-26 | |
| 2023-09-30 | $35.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $85.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $1.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $223.00K 10-K · filed 2025-03-04 | |
| 2022-09-30 | $50.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $37.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $250.00K 10-K · filed 2023-03-23 | |
| 2021-09-30 | $50.00K 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $200.00K 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $741.00K 10-K · filed 2022-03-03 | |
| 2020-09-30 | $702.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $10.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $10.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $2.61M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $253.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $116.00K 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $1.48M 10-Q · filed 2020-11-09 | |
| 2018-12-31 | $5.11M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $1.35M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $1.56M 10-Q · filed 2019-11-05 | |
| 2018-03-31 | $1.55M 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $927.00K 10-K · filed 2020-03-02 | |
| 2016-12-31 | $258.00K 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |